| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000024395 |
| Receipt No. | R000028080 |
| Official scientific title of the study | Prospective evaluation of the factors in geriatric assessment for predicting the vulnerability of the elderly patients in out-patient chemotherapy |
| Date of disclosure of the study information | 2016/11/01 |
| Last modified on | 2016/10/13 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Prospective evaluation of the factors in geriatric assessment for predicting the vulnerability of the elderly patients in out-patient chemotherapy | |
| Title of the study (Brief title) | Prospective evaluation of the factors in geriatric assessment for predicting the vulnerability of the elderly patients in out-patient chemotherapy | |
| Region |
|
|
| Condition | ||||
| Condition | Elderly cancer patients with solid tumors | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To prospectively investigate which tools for ADL assessent (MOS-ADL, KPS, G8, or VES-13) could best predict the tolerability of the out-patient chemotherapy |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | To investigate which tools for ADL assessent (MOS-ADL, KPS, G8, or VES-13) could best predict the tolerability of the out-patient chemotherapy |
| Key secondary outcomes | To investigate the tolerability of the chemotherapy regimens selected by physician's subjective evaluation and CGA components independently associated with the tolerability. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) with 70 years of age or older
(2) with a histologically confirmed diagnosis of cancer at any stage (3) those planing to continue chemotherapy more than 3 months (4) those fluent in Japanese |
|||
| Key exclusion criteria | (1) with disturbance of consciousness
(2) with severe physical impairment (3) with severe mental disorder (4) with hematologic malignancy (4) those considered inappropriate for the participation |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Yuichi Ando |
| Organization | Nagoya University Hospital |
| Division name | Clinical Oncology and Chemotherapy |
| Address | 65 Tsuruma, Showa-ku, Nagoya, Japan |
| TEL | 052-741-1903 |
| yando@med.nagoya-u.ac.jp | |
| Public contact | |
| Name of contact person | Ayumu Matsuoka |
| Organization | Nagoya University Hospital |
| Division name | Clinical Oncology and Chemotherapy |
| Address | 65 Tsuruma, Showa-ku, Nagoya, Japan |
| TEL | 052-741-1903 |
| Homepage URL | |
| ayumu0611@med.nagoya-u.ac.jp | |
| Sponsor | |
| Institute | Nagoya University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Management Expenses Grants |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | (1) Completion of cancer-specific geriatric assessment before the initiation of the out-patient chemotherapy
(2) Measurement of MOS-ADL, KPS, G8, VES-13 and grip strength every month |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028080 |